MedPath

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Registration Number
NCT00282022
Lead Sponsor
Vion Pharmaceuticals
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well VNP40101M works in treating patients with recurrent or refractory locally advanced or metastatic small cell lung cancer.

Detailed Description

OBJECTIVES:

* Determine the overall response rate (partial and complete) in patients with relapsed or refractory locally advanced or metastatic small cell lung cancer treated with VNP40101M.

* Determine the toxic effects of this drug in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to disease state (sensitive relapse \[progressive disease \> 3 months after responding to first-line chemotherapy\] vs resistant disease \[progressive disease during or ≤ 3 months after first-line chemotherapy\]).

Patients receive VNP40101M IV over 15-30 minutes once weekly for 3 weeks. Treatment repeats every 6 weeks for up to 6 courses. Patients achieving a complete response (CR) receive 2 additional courses of therapy after CR.

After completion of study treatment, patients are followed periodically for up to 18 months.

PROJECTED ACCRUAL: A total of 87 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
87
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Toxicity
Overall response rate (complete and partial response)
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

USC/Norris Comprehensive Cancer Center and Hospital

🇺🇸

Los Angeles, California, United States

Yale Cancer Center

🇺🇸

New Haven, Connecticut, United States

Veterans Affairs Medical Center - West Haven

🇺🇸

West Haven, Connecticut, United States

Helen F. Graham Cancer Center at Christiana Hospital

🇺🇸

Newark, Delaware, United States

Albert Einstein Cancer Center at Albert Einstein College of Medicine

🇺🇸

Bronx, New York, United States

Cleveland Clinic Taussig Cancer Center

🇺🇸

Cleveland, Ohio, United States

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Sarah Cannon Cancer Center at Centennial Medical Center

🇺🇸

Nashville, Tennessee, United States

M. D. Anderson Cancer Center at University of Texas

🇺🇸

Houston, Texas, United States

USC/Norris Comprehensive Cancer Center and Hospital
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.